NCT06300580View on ClinicalTrials.gov

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

May 26, 2025

Study Completion Date

May 26, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

ABBV-932

Oral Capsule

Trial Locations (1)

HA1 3UJ

Parexel Early Phase Clinical Unit /ID# 264286, Harrow

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY